These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21250937)

  • 1. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam.
    Pizza V; Busillo V; Agresta A; Bisogno A; Capasso A
    Cent Nerv Syst Agents Med Chem; 2011 Mar; 11(1):31-4. PubMed ID: 21250937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study.
    Brighina F; Palermo A; Aloisio A; Francolini M; Giglia G; Fierro B
    Clin Neuropharmacol; 2006; 29(6):338-42. PubMed ID: 17095897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of levetiracetam in pediatric migraine.
    Miller GS
    Headache; 2004 Mar; 44(3):238-43. PubMed ID: 15012661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review.
    Watkins AK; Gee ME; Brown JN
    J Clin Pharm Ther; 2018 Aug; 43(4):467-475. PubMed ID: 29781197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
    Evers S; Frese A; Summ O; Husstedt IW; Marziniak M
    Cephalalgia; 2022 Oct; 42(11-12):1218-1224. PubMed ID: 35633027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam prophylaxis in pediatric migraine--an open-label study.
    Pakalnis A; Kring D; Meier L
    Headache; 2007 Mar; 47(3):427-30. PubMed ID: 17371359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W; Shaw J; Bloom M; Gebeline-Myers C
    Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial.
    Kashipazha D; Ghadikolaei HS; Siavashi M
    Curr Clin Pharmacol; 2017; 12(1):55-59. PubMed ID: 28356053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levetiracetam as migraine prophylaxis.
    Cochran JW
    Clin J Pain; 2004; 20(3):198-9. PubMed ID: 15100599
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiepileptic drugs in migraine prophylaxis: state of the art.
    Capuano A; Vollono C; Mei D; Pierguidi L; Ferraro D; Di Trapani G
    Clin Ter; 2004; 155(2-3):79-87. PubMed ID: 15244112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India.
    Verma A; Srivastava D; Kumar A; Singh V
    Clin Neuropharmacol; 2013; 36(6):193-7. PubMed ID: 24201237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of levetiracetam for migraine prophylaxis: A systematic review and meta-analysis.
    Yen PH; Kuan YC; Tam KW; Chung CC; Hong CT; Huang YH
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):755-764. PubMed ID: 32861551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
    Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
    Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial.
    Montazerlotfelahi H; Amanat M; Tavasoli AR; Agah E; Zamani GR; Sander JW; Badv RS; Mohammadi M; Dehghani M; Heidari M; Hosseini SA; Salehi M; Ashrafi MR
    Cephalalgia; 2019 Oct; 39(12):1509-1517. PubMed ID: 31154809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of levetiracetam for partial seizures.
    Abou-Khalil B; Schaich L
    Seizure; 2005 Dec; 14(8):577-85. PubMed ID: 16280250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study.
    Morrell MJ; Leppik I; French J; Ferrendelli J; Han J; Magnus L
    Epilepsy Res; 2003 May; 54(2-3):153-61. PubMed ID: 12837566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiepileptic drugs in pediatric migraine].
    Cuvellier JC; Riquet A; Vallée L
    Arch Pediatr; 2008 Nov; 15(11):1693-9. PubMed ID: 18829273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.